ERBB2 and neoplasm: 89Zr-trastuzumab has been used for the detection of human epidermal growth factor 2 (HER2)-positive metastases developed in patients with HER2-negative tumours [12]; 18F-Fluciclovine uptake has shown good correlation with treatment response to neoadjuvant systemic treatments [13], as well as a higher sensitivity for infiltrating lobular carcinoma (ILC) [14].